Table 1.
Establishment of Breast Cancer Cellular Resistant Models
| IC50 ± SEM | BT-549 |
|||
|---|---|---|---|---|
| Par | r5-FU | rDOC | rDOX | |
| 5-Fluorouracil (μg/ml) | 0.63 ± 0.21 | 5.89 ± 0.47 | 4.24 ± 1.39 | 3.37 ± 0.13 |
| Docetaxel (ng/ml) | 8.12 ± 0.84 | 12.82 ± 1.67 | 212.56 ± 1.20 | 37.09 ± 2.18 |
| Doxorubicin (ng/ml) | 9.46 ± 1.62 | 15.97 ± 1.26 | 180.6 ± 2.09 | 84.38 ± 1.92 |
| IC50 ± SEM | MDA-MB-468 |
|||
|---|---|---|---|---|
| Par | r5-FU | rDOC | rDOX | |
| 5-Fluorouracil (μg/ml) | 1.16 ± 0.14 | 18.97 ± 0.29 | 5.97 ± 0.07 | 4.28 ± 0.83 |
| Docetaxel (ng/ml) | 9.74 ± 1.02 | 12. 62 ± 0.86 | 63.07 ± 1.93 | 13.47 ± 0.32 |
| Doxorubicin (ng/ml) | 116 ± 1.69 | 129.20 ± 1.95 | 338.47 ± 1.40 | 536.47 ± 1.79 |
Breast cancer cell line BT-549 was adapted to grow isolatedly with 2000 ng/ml of 5-FU, 40 ng/ml of DOC and 20 ng/ml of DOX; MDA-MB-468 cell line was grown similarly with 2000 ng/ml of 5-FU, 20 ng/ml of DOC and 200 ng/ml of DOX. Then 50% inhibitory concentration (IC50) value of each drug was determined by MTT assay. The values are means of three independent experiments performed in triplicate ± SEM. p values<0.05 were considered to be statistically significant.